In the Journals

Triple therapy resulted in reduced fibrosis among patients with HCV

February 11, 2014
Liver transplant patients with recurrent hepatitis C virus displayed less fibrotic progression when treated with tacrolimus, azathioprine and…
Industry News

Gilead submits fixed-dose combination ledipasvir/sofosbuvir HCV tablet for FDA approval

February 10, 2014
“Today’s filing brings us one step closer to our goal of offering all patients with hepatitis C a simple, safe and highly effective…
Industry News

Sovaldi sales help push revenue increases for Gilead Sciences

February 5, 2014
Boosted by a 15% increase in 2013 antiviral product sales over the previous year, Gilead Sciences announced fourth-quarter sales were up 21% from…

Investigational HCV combination treatment yielded high SVR rate

January 31, 2014
AbbVie has announced sustained virological response rates of up to 99% associated with its investigational all-oral, interferon-free therapy for…

AASLD, IDSA, IAS-USA release guidelines, launch website for management of HCV

January 29, 2014
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, in collaboration with the International…
In the Journals

Oral antivirals, ribavirin efficacious in patients with HCV genotype 1

January 27, 2014
A combination of protease inhibitor ABT-450 plus ritonavir, ribavirin, nonnucleoside polymerase inhibitor ABT-333, and NS5A inhibitor ABT-267…
In the Journals

HCV testing rates low among IDUs in Thailand

January 22, 2014
Only one-third of Thai injection drug users reported getting tested for hepatitis C, according to study results published in the Journal of Public
In the Journals

Lymphocyte count associated with infection risk during interferon treatment

January 21, 2014
Adults with hepatitis C who were treated with pegylated interferon and ribavirin for up to 48 weeks commonly experienced moderate, severe or…
In the JournalsPerspective

Prevalence of hepatitis C in Swiss MSM similar to general population

January 20, 2014
In Switzerland, hepatitis C virus infections do not appear to be more prevalent in men with or without HIV than in the general population, suggesting…
Regulatory News

Sovaldi OK’d for marketing throughout European Union

January 17, 2014
The European Commission granted marketing authorization to Gilead Sciences for once-daily Sovaldi with ribavirin and/or interferon for treatment of…